HCPLive Network

Drug Reduces Progression to Clinically Definite MS

Friday, April 20 (HealthDay News) --  As part of a Phase 3 trial, Mark Freedman, M.D., from the University of Ottawa in Canada, and colleagues randomly assigned 517 individuals who had a first clinical demyelinating event and brain lesions detected by magnetic resonance imaging (MRI) to a subcutaneous serum-free formulation of IFN β-1a one or three times a week, or placebo. Placebo patients were switched to IFN β-1a three times a week after two years or after a diagnosis of clinically definite MS.

At three years, the researchers found that the probability of developing clinically definite MS was 41.3 percent for placebo patients switched to IFN β-1a, but was significantly lower for those who received IFN β-1a once a week (27.6 percent) or three times a week (27.1 percent). Similar results were found for the probability of a McDonald MS diagnosis, at 86.5, 79.1, and 66.8 percent, respectively.

"While doses three times a week and once a week equally delayed a clinically definite MS diagnosis without MRI measures, there were significantly more benefits in taking the drug three times a week compared with once a week when it came to brain lesion changes and other McDonald criteria for diagnosing MS," Freedman said in a statement.

The study was supported by Merck Serono S.A.

Press Release
More Information

Individuals suspected of having multiple sclerosis are less likely to be diagnosed with clinically definite disease if they soon start treatment with interferon β-1a, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.

Copyright © 2012 HealthDay. All rights reserved.

Further Reading
Pain is a common symptom in patients with multiple sclerosis (MS), with some studies showing that clinically significant pain associated with their disease is experienced by more than half of patients with MS.
Successfully treating and reversing the effects of multiple sclerosis may one day be possible using a drug originally developed to treat chronic pain.
Results from the CLARITY study show cladribine reduces the relapse rate in multiple sclerosis patients who have failed other disease-modifying therapies.
Though Teva Pharmaceutical Industries Ltd.’s Copaxone (glatiramer acetate) treatment for relapsing-remitting multiple sclerosis (RRMS) is solely approved by the US Food and Drug Administration (FDA) for use in its once-daily 20 milligram per 1 milliliter dosage form, results of a recent late-stage clinical trial found the drug more significantly reduced relapse rates when injected less frequently at a higher dose.
Mindfulness meditation can improve fatigue, depression, and other measure of quality of life in patietns with multiple sclerosis.
Study results show that oral laquinimod reduces the annual relapse rate in patients with relapsing-remitting multiple sclerosis.
Study finds no improvement in cognitive impairment among patients with multiple sclerosis treated with ginkgo biloba extract.
More Reading